Benitec Settles Suit Vs. Genscript Over RNAi Patent
As part of the settlement, Genscript has taken from Benitec a worldwide non-exclusive license to make and sell DNA directed RNAi (ddRNAi) based products, Benitec said.
Earlier this month, the Australian biotech company settled with Ambion another defendant in the same law suit. Ambion also agreed to take a non-exclusive license, but financial details...
To view the full article, register now.